Temozolomide and Other Potential Agents for the Treatment of Glioblastoma Multiforme

被引：57
作者：
Nagasawa, Daniel T. [1 ]
Chow, Frances [1 ]
Yew, Andrew [1 ]
Kim, Won [1 ]
Cremer, Nicole [1 ]
Yang, Isaac [1 ]
机构：
[1] Univ Calif Los Angeles, David Geffen Sch Med, UCLA Dept Neurosurg, Los Angeles, CA 90095 USA
来源：
NEUROSURGERY CLINICS OF NORTH AMERICA | 2012年 / 23卷 / 02期
关键词：
Temozolomide; Glioblastoma multiforme; BCNU wafers; Bevacizumab; NovoTTF-100A; NEWLY-DIAGNOSED GLIOBLASTOMA; HIGH-GRADE GLIOMAS; PHASE-II TRIAL; HUMAN-MALIGNANT GLIOMA; BEVACIZUMAB PLUS IRINOTECAN; MGMT PROMOTER METHYLATION; PROGRESSION-FREE SURVIVAL; BASE EXCISION-REPAIR; CANCER STEM-CELLS; QUALITY-OF-LIFE;
D O I：
10.1016/j.nec.2012.01.007
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
This article provides historical and recent perspectives related to the use of temozolomide for the treatment of glioblastoma multiforme. Temozolomide has quickly become part of the standard of care for the modern treatment of stage IV glioblastoma multiforme since its approval in 2005. Yet despite its improvements from previous therapies, median survival remains approximately 15 months, with a 2-year survival rate of 8% to 26%. The mechanism of action of this chemotherapeutic agent, conferred advantages and limitations, treatment resistance and rescue, and potential targets of future research are discussed.
引用
收藏
页码：307 / +
页数：17
相关论文
共 153 条
  • [1] A new schedule of fotemustine in temozolomide-pretreated patients with relapsing glioblastoma
    Addeo, Raffaele
    Caraglia, Michele
    De Santi, M. Serena
    Montella, Liliana
    Abbruzzese, Alberto
    Parlato, Ciro
    Vincenzi, Bruno
    Carraturo, Marco
    Faiola, Vincenzo
    Genovese, Michele
    Cennamo, Gregorio
    Del Prete, Salvatore
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2011, 102 (03) : 417 - 424
  • [2] Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme
    Athanassiou, H
    Synodinou, M
    Maragoudakis, E
    Paraskevaidis, M
    Verigos, C
    Misailidou, D
    Antonadou, D
    Saris, G
    Beroukas, K
    Karageorgis, P
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (10) : 2372 - 2377
  • [3] Baker SD, 1999, CLIN CANCER RES, V5, P309
  • [4] Radiotherapy and concomitant temozolomide during the first and last weeks in high grade gliomas: long-term analysis of a phase II study
    Balducci, Mario
    D'Agostino, Giuseppe Roberto
    Manfrida, Stefania
    De Renzi, Filippo
    Colicchio, Gabriella
    Apicella, Giuseppina
    Mangiola, Annunziato
    Fiorentino, Alba
    Frascino, Vincenzo
    Mantini, Giovanna
    De Bari, Berardino
    Pompucci, Angelo
    Valentini, Vincenzo
    Anile, Carmelo
    Cellini, Numa
    [J]. JOURNAL OF NEURO-ONCOLOGY, 2010, 97 (01) : 95 - 100
  • [5] The relationship between six-month progression-free survival and 12-month overall survival end points for phase II trials in patients with glioblastoma multiforme
    Ballman, Karla V.
    Buckner, Jan C.
    Brown, Paul D.
    Giannini, Caterina
    Flynn, Patrick J.
    LaPlant, Betsy R.
    Jaeckle, Kurt A.
    [J]. NEURO-ONCOLOGY, 2007, 9 (01) : 29 - 38
  • [6] Safety and pharmacokinetics of temozolomide using a dose-escalation, metronomic schedule in recurrent paediatric brain tumours
    Baruchel, S.
    Diezi, M.
    Hargrave, D.
    Stempak, D.
    Gammon, J.
    Moghrabi, A.
    Coppes, M. J.
    Fernandez, C. V.
    Bouffet, E.
    [J]. EUROPEAN JOURNAL OF CANCER, 2006, 42 (14) : 2335 - 2342
  • [7] Antiangiogenic agents in the treatment of recurrent or newly diagnosed glioblastoma: Analysis of single-agent and combined modality approaches
    Beal, Kathryn
    Abrey, Lauren E.
    Gutin, Philip H.
    [J]. RADIATION ONCOLOGY, 2011, 6
  • [8] Effect of gastric pH on the relative oral bioavailability and pharmacokinetics of temozolomide
    Beale, P
    Judson, I
    Moore, S
    Statkevich, P
    Marco, A
    Cutler, DL
    Reidenberg, P
    Brada, M
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 1999, 44 (05) : 389 - 394
  • [9] Temozolomide preferentially depletes cancer stem cells in glioblastoma
    Beier, Dagmar
    Roehrl, Stefanie
    Pillai, Deepu R.
    Schwarz, Stefanie
    Kunz-Schughart, Leoni A.
    Leukel, Petra
    Proescholdt, Martin
    Brawanski, Alexander
    Bogdahn, Ulrich
    Trampe-Kieslich, Ariane
    Giebel, Bernd
    Wischhusen, Joerg
    Reifenberger, Guido
    Hau, Peter
    Beier, Christoph P.
    [J]. CANCER RESEARCH, 2008, 68 (14) : 5706 - 5715
  • [10] Chemoresistance of glioblastoma cancer stem cells - much more complex than expected
    Beier, Dagmar
    Schulz, Joerg B.
    Beier, Christoph P.
    [J]. MOLECULAR CANCER, 2011, 10
12345678910